Key insights from therapeutic drug monitoring in Crohn's disease patients

Inflammatory Bowel Disease

A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy

Inflamm Bowel Dis.

Yao J, Jiang X, You JHS

doi: 10.1093/ibd/izaa073.

Inflammatory Bowel Disease

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Scand J Gastroenterol.

Buer LCT, Moum BA, Cvancarova M, Warren DJ, Bolstad N, Medhus AW, Høivik ML

doi: 10.1080/00365521.

RECOMMENDED

Inflammatory Bowel Disease

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Clin Gastroenterol Hepatol.

Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Casteele NV, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, Jones J, Kaplan GG, Sparrow MP, Velayos FS, Ullman T, Siegel CA

doi: 10.1016/j.cgh.

Inflammatory Bowel Disease

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

Inflamm Bowel Dis.

Lyles JL, Mulgund AA, Bauman LE, Su W, Fei L, Chona DL, Sharma P, Etter RK, Hellmann J, Denson LA, Minar P, Dykes DM, Rosen MJ

doi: 10.1093/ibd/izaa102.

RECOMMENDED

Inflammatory Bowel Disease

Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus

Digestion.

Greuter T, Maillard MH, Juillerat P, Michetti P, Seibold F, Mottet C, Zahnd N, Sauter B, Schoepfer AM, Rogler G, Vavricka SR, on behalf of the Swiss IBDnet, an official working group of the Swiss Society of Gastroenterology.

doi: 10.1159/000501930.

Inflammatory Bowel Disease

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring

Aliment Pharmacol Ther.

Lucidarme C, Petitcollin A, Brochard C, Siproudhis L, Dewitte M, Landemaine A, Bellissant E, Bouguen G

doi: 10.1111/apt.15046.

Inflammatory Bowel Disease

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Lancet Gastroenterol Hepatol.

Kennedy NA, Heap GA, Green HD, Hamilton B, Bewshea C, Walker GJ, Thomas A, Nice R, Perry MH, Bouri S, Chanchlani N, Heerasing NM, Hendy P, Lin S, Gaya DR, Cummings JRF, Selinger CP, Lees CW, Hart AL, Parkes M, Sebastian S, Mansfield JC, Irving PM, Lindsay J, Russell RK, McDonald TJ, McGovern D, Goodhand JR, Ahmad T; UK Inflammatory Bowel Disease Pharmacogenetics Study Group

doi: 10.1016/S2468-1253(19)30012-3.

Inflammatory Bowel Disease

Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease

Inflamm Bowel Dis.

Fernandes SR, Bernardo S, Simões C, Gonçalves AR, Valente A, Baldaia C, Moura Santos P, Correia LA, Tato Marinho R

doi: 10.1093/ibd/izz131.

Inflammatory Bowel Disease

Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy

J Crohns Colitis.

Messadeg L, Hordonneau C, Bouguen G, Goutorbe F, Reimund JM, Goutte M, Boucher AL, Scanzi J, Reymond M, Allimant C, Dapoigny M, Pereira B, Bommelaer G, Buisson A

doi: 10.1093/ecco-jcc/jjaa098.

Related content

A Systematic Review on Cost-effectiveness Analyses of Therapeutic Drug Monitoring for Patients with Inflammatory Bowel Disease: From Immunosuppressive to Anti-TNF Therapy

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort

Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases

Effect of a Practice-wide Anti-TNF Proactive Therapeutic Drug Monitoring Program on Outcomes in Pediatric Patients with Inflammatory Bowel Disease

Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus

Predictors of relapse following infliximab de-escalation in patients with inflammatory bowel disease: the value of a strategy based on therapeutic drug monitoring

Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study

Proactive Infliximab Drug Monitoring Is Superior to Conventional Management in Inflammatory Bowel Disease

Early Transmural Response Assessed Using Magnetic Resonance Imaging Could Predict Sustained Clinical Remission and Prevent Bowel Damage in Patients with Crohn's Disease Treated with Anti-Tumour Necrosis Factor Therapy